This trial will Study a type of sarcoma defined metastatic soft-tissue sarcoma (STS). Participants will be treated with bexmarilimab, a CLEVER-1 antibody plus doxorubicin, a chemotherapy. The main purpose of the Study is to analyze the safety (to find out how safe or toxic a treatment is to appropriately manage the risks) and efficacy (to find out how effective a treatment is) of bexmarilimab combined with doxorubicin in participants who have STS.

Start Date01 Jul 2026

Sponsor / Collaborator

Medica Scientia Innovation Research SL

[+1]

NCT05171062

/ WithdrawnPhase 1IIT

Safety and Tolerability of Bexmarilimab Plus Pembrolizumab for Patients With Advanced (Inoperable or Metastatic) Non-small Cell Lung Cancer (NSCLC)

This study enrolls patients with Non-small cell lung cancer and treats them with the investigational drug Bexmarilimab (FP-1305) plus standard of care Pembrolizumab to block Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1). Treating with an antiCLEVER-1 antibody, such as bexmarilimab, could lead to immune system activation, which, in turn, may lead to cancer elimination.

Start Date01 Jun 2023

Sponsor / Collaborator

University of Texas Health Science Center At San Antonio

[+1]

NCT05428969

/ Active, not recruitingPhase 1/2

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.

Start Date02 Jun 2022

Sponsor / Collaborator

Faron Pharmaceuticals Oy

100 Clinical Results associated with Bexmarilimab

100 Translational Medicine associated with Bexmarilimab

100 Patents (Medical) associated with Bexmarilimab

Literatures (Medical) associated with Bexmarilimab

12 Dec 2025·Immunotherapy

Clinical optimization of bexmarilimab as a myeloid checkpoint therapy

Review

Author: Karthikeyan, Mahalakshmi ; Mickos, Jesper ; Hollmén, Maija

Checkpoint blockade has revolutionized cancer therapy, yet durable responses are limited by myeloid-driven immunosuppression. Bexmarilimab, a first-in-class monoclonal antibody targeting the scavenger receptor Clever-1 (Stabilin-1), represents a novel strategy to recondition tumor-associated macrophages and malignant myeloid cells. This review summarizes the biological rationale for Clever-1 targeting, appraises clinical and translational evidence, and outlines strategies to enhance therapeutic efficacy through patient selection, rational drug combinations, biomarker-driven patient stratification, and timing of intervention. We also highlight future opportunities for integrating bexmarilimab with next-generation immunotherapies and precision medicine approaches.

01 Nov 2025·Journal for ImmunoTherapy of Cancer

Correction: Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment

Article

01 Jul 2025·Lancet Haematology

Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial

Article

Author: Ylitalo, Arno ; Stein, Anthony Selwyn ; Rimpiläinen, Johanna ; Fjällskog, Marie-Louise ; Daver, Naval ; Aakko, Sofia ; Kontro, Mika ; Pyörälä, Marja ; Hollmén, Maija ; Jalkanen, Juho ; Pawlitzky, Inka ; Siitonen, Timo

BACKGROUND:

Bexmarilimab blocks Clever-1 on macrophages to enhance antigen presentation and T cell activation. Because Clever-1 is expressed by myeloid leukaemia cells, bexmarilimab may combat leukaemia and influence the tumour microenvironment to augment the effectiveness of standard-of-care therapy in patients with myelodysplastic syndrome and acute myeloid leukaemia. The aim of this study was to determine the safety of bexmarilimab in combination with standard-of-care treatment in myelodysplastic syndrome and acute myeloid leukaemia and to identify the recommended dose for expansion of bexmarilimab in combination with standard of care.

METHODS:

The phase 1 dose-escalation part of this multicentre, single-arm, phase 1/2 study was done at six centres in Finland and the USA. Patients aged 18 years or older (Eastern Cooperative Oncology Group performance status of 2 or less) with myelodysplastic syndrome (2016 WHO) with a Revised International Prognostic Scoring System (IPPS-R) score of 3·5 or more for USA (3·0 for the European Union), chronic myelomonocytic leukaemia (2016 WHO) with 10-19% marrow blasts, myelodysplastic syndrome or chronic myelomonocytic leukaemia with no response to or disease progression during hypomethylating agent treatment, or relapsed or refractory acute myeloid leukaemia were treated with escalating doses of bexmarilimab (1·0 mg/kg, 3·0 mg/kg, and 6·0 mg/kg, intravenous, once weekly, 28-day cycle) in combination with azacitidine, administered as per label. Here we report the phase 1 part of the study, for which the primary outcome was safety (the incidence and frequency of dose limiting toxicities and the frequency and severity of adverse events) as well as the determination of the maximum tolerated dose and recommended expansion dose for the phase 2 part using a Bayesian optimal interval design. All patients receiving at least one dose of bexmarilimab were included in safety analyses, and those with a post-baseline activity assessment were included in activity analyses. This trial is registered with ClinicalTrials.gov (NCT05428969) and EudraCT (2021-002104-12) databases. Phase 2 of the study is ongoing in patients with myelodysplastic syndrome with no response to hypomethylating agent.

FINDINGS:

Between June 2, 2022, and Dec 7, 2023, 33 patients (14 with myelodysplastic syndrome, 19 with relapsed or refractory acute myeloid leukaemia) were enrolled in phase 1; no patients with chronic myelomonocytic leukaemia were identified. 19 (58%) patients were male and 14 (42%) were female, and 24 (73%) patients were non-Hispanic ethnicity, and eight (24%) were White. Median follow-up time for all patients was 6·2 months (IQR 3·5-10·7). The maximum tolerated dose was not reached, and the recommended expansion dose for phase 2 was established as 6·0 mg/kg in patients with myelodysplastic syndrome with no response to hypomethylating agents. There were no dose-limiting toxicities. The most common grade 3-4 treatment-emergent adverse events were febrile neutropenia (n=8 [24%]), anemia (n=7 [21%]), and thrombocytopenia (n=5 [15%]). Treatment-emergent deaths occurred as a result of sepsis (n=1 [3%]), neutropenic infection (n=1 [3%]), and haemophagocytic lymphohistiocytosis (n=1 [3%]). Four patients presented treatment-related serious adverse events, one patient in the 1·0 mg/kg group, two in the 3·0 mg/kg group and one in the 6·0 mg/kg group. These included rash (grade 3), capillary leak syndrome (grade 3), cryptogenic organising pneumonia (grade 3) and haemophagocytic lymphohistiocytosis (grade 5) which led to one death. The objective response rate was 45% (15 of 33; 95% CI 28-62) across all doses.

INTERPRETATION:

Bexmarilimab in combination with azacitidine has a manageable safety profile, consistent with azacitidine, and shows promising clinical activity in patients with high-risk myelodysplastic syndrome.

FUNDING:

Faron Pharmaceuticals.

News (Medical) associated with Bexmarilimab

26 Mar 2026

·www.biospace.com

Faron Pharmaceuticals Ltd: Faron Appoints New CTO to Strengthen Late-Stage Development Activities

TURKU, FI / ACCESS Newswire / March 26, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company, announces the appointment of Mr. Heikki Jouttijärvi as the Company's Chief Technical Officer (CTO). Heikki Jouttijärvi brings decades of experience in biopharma manufacturing, supply chain management and commercial operations. Most recently, he has been the SVP of Commercial Business Operations at Adverum Biotechnologies, Inc that was acquired by Eli Lilly. Prior to that Mr. Jouttijärvi has held various global roles at Menlo Therapeutics, Inc and Santen Pharmaceutical Company, Ltd. He holds a M.Sc degree in Pharmacy from the University of Helsinki. "We are extremely happy to welcome Heikki as a part of the Faron team . His wealth of experience with commercial operations, manufacturing and supply chain management with late-stage and approved drugs is incredibly valuable for us as we progress with bexmarilimab to the announced Phase IIb trial in HR MDS", comments Dr. Juho Jalkanen, CEO of Faron. "I am honored to join the Faron team at this exciting point in time in the development of bexmarilimab. I have been amazed by the resilience and excellent hard work done with bexmarilimab to date and I am humbled to be able to join the program at this stage. We look forward to advance the program to the benefit patients, whom deserve our ultimate commitment", says Mr. Jouttijärvi, newly appointed CTO of Faron Pharmaceuticals. For more information, please contact: IR Partners, Finland (Media) Kare Laukkanen +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi FINN Partners, US (Media) Alyssa Paldo +1 847 791-8085 alyssa.paldo@finnpartners.com Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner +44 (0) 207 213 0880 Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä +358 (0)40 555 4727 +358 (0)50 553 8990 About bexmarilimab Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care. About Faron Pharmaceuticals Ltd Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The company's lead asset, bexmarilimab , is a novel macrophage-guiding immunotherapy being investigated in multiple oncology settings. Further information is available at . Forward-Looking Statements This press release contains certain forward-looking statements relating to the business of Faron Pharmaceuticals. In addition, even if the actual results or development of Faron Pharmaceuticals are consistent with the forward-looking statements contained in this press release, those results or developments of Faron Pharmaceuticals may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Faron Pharmaceuticals as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Faron Pharmaceuticals could be affected by, among other things, uncertainties and delays involved in the development of product candidates, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, inflation, changes in tariff policies, political or macroeconomic developments, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Faron Pharmaceuticals is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. SOURCE: Faron Pharmaceuticals View the original press release on ACCESS Newswire

Executive ChangeImmunotherapyPhase 2

19 Mar 2026

·www.biospace.com

Faron Pharmaceuticals Ltd: Director Dealing

TURKU, FI / ACCESS Newswire / March 19, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Juho Jalkanen, CEO of the Company, subscribed 23,656 ordinary shares in Faron at price of EUR 0.5 per share on 17 March 2026, pursuant to the rights issue announced by the Company on 10 March 2026. Additionally, Juho Jalkanen subscribed 4,860 ordinary shares in Faron at a price of EUR 0.5 per share on 17 March 2026 on behalf of persons closely associated. Further details are set out in the Notification of Dealing Form below. For more information, please contact: IR Partners, Finland (Media) Kare Laukkanen +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi FINN Partners, US (Media) Alyssa Paldo +1 847 791-8085 alyssa.paldo@finnpartners.com Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner +44 (0) 207 213 0880 Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä +358 (0)40 555 4727 +358 (0)50 553 8990 About bexmarilimab Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care. About Faron Pharmaceuticals Ltd Faron (AIM:FARN)(First North:FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab , a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated/persons subject to the notification requirement a. Name Juho Jalkanen Eveliina Jalkanen Esko Jalkanen Aaro Jalkanen Enna Jalkanen Heikki Jalkanen 2 Reason for notification a. Position/Status CEO PCA PCA PCA PCA PCA b. Initial notification/ Amendment Initial Notification c. Reference number 148007/7/4 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Faron Pharmaceuticals Ltd. b. LEI 7437009H31TO1DC0EB42 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a. Description of the financial instrument, type of instrument Identification Code Share ISIN: FI4000153309 b. Nature of the transaction Subscription Price(s) per share (p) Volume(s) EUR 0.5 EUR 0.5 EUR 0.5 EUR 0.5 EUR 0.5 EUR 0.5 23,796 1,377 684 1,431 684 684 d. Aggregated information Volume Price Transaction details (a) (1): Volume 23,796 Unit price: 0.5 EUR (2): Volume 1,377 Unit price: 0.5 EUR (1): Volume 684 Unit price: 0.5 EUR (1): Volume 1,431 Unit price: 0.5 EUR (1): Volume 684 Unit price: 0.5 EUR (1): Volume 684 Unit price: 0.5 EUR e. Date of the transaction 17.3.2026 (outside a trading venue) f. Venue Nasdaq First North Growth Market SOURCE: Faron Pharmaceuticals View the original press release on ACCESS Newswire

Immunotherapy

09 Mar 2026

·www.biospace.com

Update to Faron’s Financial Calendar and Date of the Annual General Meeting in 2026

TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces an update for the Company's financial calendar 2026. The Annual General Meeting is now planned to take place on 4 May 2026, instead of 30 March 2026 as previously communicated. Faron's Board of Directors will issue a separate company announcement in due course to formally convene the meeting. The publication date of Faron's half-year financial report for the period January 1 to June 30, 2026, remains unchanged being Wednesday 26 August 2026. For more information, please contact: IR Partners, Finland (Media) Kare Laukkanen +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi FINN Partners, US (Media) Alyssa Paldo +1 847 791-8085 alyssa.paldo@finnpartners.com Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner +44 (0) 207 213 0880 Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä +358 (0)40 555 4727 +358 (0)50 553 8990 About bexmarilimab Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care. About Faron Pharmaceuticals Ltd Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The company's lead asset, bexmarilimab , is a novel macrophage-guiding immunotherapy being investigated in multiple oncology settings. Further information is available at . SOURCE: Faron Pharmaceuticals Ltd. View the original press release on ACCESS Newswire

Immunotherapy

100 Deals associated with Bexmarilimab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16383

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic Soft Tissue Sarcoma	Phase 2	-	Faron Pharmaceuticals Oy	01 Jul 2026
Chronic Myelomonocytic Leukemia	Phase 2	United States	Faron Pharmaceuticals Oy	02 Jun 2022
Chronic Myelomonocytic Leukemia	Phase 2	Finland	Faron Pharmaceuticals Oy	02 Jun 2022
Chronic Myelomonocytic Leukemia	Phase 2	United Kingdom	Faron Pharmaceuticals Oy	02 Jun 2022
Refractory acute myeloid leukemia	Phase 2	United States	Faron Pharmaceuticals Oy	02 Jun 2022
Refractory acute myeloid leukemia	Phase 2	Finland	Faron Pharmaceuticals Oy	02 Jun 2022
Refractory acute myeloid leukemia	Phase 2	United Kingdom	Faron Pharmaceuticals Oy	02 Jun 2022
Myelodysplastic Syndromes	Phase 2	United States	Faron Pharmaceuticals Oy	02 Jun 2022
Myelodysplastic Syndromes	Phase 2	Finland	Faron Pharmaceuticals Oy	02 Jun 2022
Myelodysplastic Syndromes	Phase 2	United Kingdom	Faron Pharmaceuticals Oy	02 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05428969 (BEXMAB, ESMO2025)	Phase 1/2	Myelodysplastic Syndromes First line	52	bexmarilimab + azacitidine (frontline HR MDS)	vjswezgyhz(hndcesssaw) = 25% increase of BM CD8+ T cells, already after cycle 1 uwclmuasyl (yffytmugws ) View more	Positive	17 Oct 2025
				bexmarilimab + azacitidine (relapsed/refractory (r/r) MDS)
NCT05428969 (Pubmed \| Lancet Haematol)	Phase 1/2	Acute Myeloid Leukemia \| High Risk Myelodysplastic Syndrome	33	Bexmarilimab + Azacitidine	vlfabqmhzy(opzbgeduzw) = anemia (n=7 [21%]) gmivjtxlfo (rncwlqasgl ) View more	Positive	01 Jul 2025
BEXMAB (EHA2025)	Phase 1/2	Myelodysplastic Syndromes	55	Bexmarilimab 1mg/kg	dlnyeowlov(mketcybnar) = yobnisfzys gasgjwggjs (aarygzuhtk )	Positive	14 May 2025
				Bexmarilimab 3mg/kg	dlnyeowlov(mketcybnar) = afkogkkqxf gasgjwggjs (aarygzuhtk )
NCT03733990 (MATINS, CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm	216	FP-1305 (bexmarilimab) (FP-1305 (Bexmarilimab) 0.3 mg/kg)	hlilznqyyn = slzyrwwvod hknwwegaeu (xzhefkybbe, bfofoluokv - ibzgezvqlz) View more	-	02 Apr 2025
				FP-1305 (bexmarilimab) (FP-1305 (Bexmarilimab) 1 mg/kg)	hlilznqyyn = hwfvddjdec hknwwegaeu (xzhefkybbe, kbttrgndmt - onfieunpfm) View more
NCT05428969 (BEXMAB, ASH2024) Manual	Phase 1/2	Myelodysplastic Syndromes TP53 Mutation	14	Bexmarilimab+Azacitidine	ddumvtfpiu(enbyuvfrrt) = xawqmixijf nwjqdvuoyn (zyrlfbdeee ) View more	Positive	09 Dec 2024
NCT05428969 (BEXMAB, Biospace) Manual	Phase 1	Myeloid Leukemia Second line \| First line TP53 Mutation	28	bexmarilimab + azacitidine	nbykaylskh(rrhmnkppru) = wrqwdyzuqd mbdqxcxcis (sdsbnlqbko )	Positive	11 Dec 2023
				bexmarilimab + azacitidine (previously HMA-failed)	nbykaylskh(rrhmnkppru) = lhyheostfj mbdqxcxcis (sdsbnlqbko )
NCT03733990 (MATINS, Pubmed \| Cell Rep Med)	Phase 1/2	Solid tumor Clever-1 \| interferon γ (IFNγ)	-	Bexmarilimab	ddxjeqfeax(lyiyhinajf) = litvpclqjl tmvkskxalf (nddacqugzg )	Positive	01 Dec 2023
				Placebo	ddxjeqfeax(lyiyhinajf) = itddqjlvnw tmvkskxalf (nddacqugzg )
NCT03733990 (MATINS, SITC2023)	Phase 1/2	Advanced Malignant Solid Neoplasm Clever-1 \| IFNg \| proinflammatory cytokines ... View more	-	Bexmarilimab (FP-1305, Bex)	ldobwfocxd(tnyomeewsn) = hboavczdoc yobnynfclw (bessmnrago )	-	02 Nov 2023
NCT03733990 (MATINS, ESMO2023)	Phase 1/2	Refractory Malignant Solid Neoplasm	216	Bexmarilimab	ncqrivnojm(mkmslnlqyd) = 15.9% of the patients experiencing grade 3-4 TRAE fwdfsfvelw (tftjmsvtfv ) View more	Positive	23 Oct 2023
NCT05428969 (BEXMAB, GlobeNewswire) Manual	Phase 1/2	Acute Myeloid Leukemia \| Myelodysplastic Syndromes	22	Bexmarilimab+standard of care	arocfzcamy(vbrbnonczb) = odpfyneizc xrmkrtmrjl (jimsshkkwb ) View more	Positive	11 Oct 2023
				Bexmarilimab+standard of care (HMA-failed MDS patients)	arocfzcamy(vbrbnonczb) = lwbuusgqrb xrmkrtmrjl (jimsshkkwb )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis